Novartis AG (XSWX:NOVNEE) Total Operating Expense: CHF20,313 Mil (TTM As of Mar. 2026)


XSWX:NOVNEE Novartis AG XSWX:NOVNEE
80 GF Score
Price CHF119.30
GF Value CHF98.21
! 7 Warning Signs
View Full Analysis

What is Novartis AG Total Operating Expense?

Novartis AG XSWX:NOVNEE -0.52% 80 Total Operating Expense is CHF20,313 Mil as of Mar. 2026. GuruFocus rates XSWX:NOVNEE with a GF Score™ of 80/100 and a GF Value™ of CHF98.21. The stock has 7 warning signs investors should review.

Novartis AG's Total Operating Expense for the three months ended in Mar. 2026 was CHF4,590 Mil. Novartis AG's Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 was CHF20,313 Mil.

Novartis AG Total Operating Expense Related Terms

Novartis AG Total Operating Expense Historical Data

* Premium members only.

The historical data trend for Novartis AG's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Novartis AG Total Operating Expense Chart

Novartis AG Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 20,430.54 22,295.98 21,117.55 21,711.35 20,186.27

Novartis AG Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5,063.03 5,407.78 5,029.76 5,285.84 4,589.96
XSWX:NOVNEE
80GF Score
Novartis AG XSWX:NOVNEE
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Novartis AG Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF20,313 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of CHF20,313 Mil mean?
Novartis AG (XSWX:NOVNEE) has a Total Operating Expense of CHF20,313 Mil as of Mar. 2026. Total operating expense is the primary recurring expense associated with central operations. View historical data on Novartis AG and its competitors.
Is Novartis AG's Total Operating Expense too high?
Novartis AG's current Total Operating Expense is CHF20,313 Mil. Overall, Novartis AG has a GF Score™ of 80/100, reflecting its overall financial health beyond just this single metric.
How does Novartis AG's Total Operating Expense compare to LLY and JNJ?
Novartis AG's Total Operating Expense of CHF20,313 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Drug Manufacturers company?
A good Total Operating Expense depends on the Drug Manufacturers industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on Novartis AG and its competitors. Novartis AG's current Total Operating Expense is CHF20,313 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novartis AG stock overvalued right now?
Novartis AG (XSWX:NOVNEE) has a current Total Operating Expense of CHF20,313 Mil. The stock's GF Value™ is CHF98.21, compared to a current price of CHF119.30 — trading 21.5% above its estimated fair value. The current Total Operating Expense is CHF20,313 Mil. Novartis AG's overall GF Score™ is 80/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For Novartis AG (XSWX:NOVNEE), the current Total Operating Expense is CHF20,313 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Novartis AG (XSWX:NOVNEE) Overvalued in 2026?

Based on GuruFocus' analysis, Novartis AG stock appears to be overvalued. The current stock price of CHF119.30 is trading 21.5% above its estimated GF Value™ of CHF98.21.

Key valuation signals for XSWX:NOVNEE:

  • Total Operating Expense: CHF20,313 Mil
  • GF Value™: CHF98.21 vs. price of CHF119.30 (21.5% above fair value)
  • GF Score™: 80/100 with 7 warning signs

No single metric tells the full story. See the XSWX:NOVNEE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Novartis AG Business Description

Address Lichtstrasse 35, Basel, CHE, 4056
Novartis develops and manufactures innovative drugs. Key areas of drug development are oncology, immunology, neuroscience, respiratory, and cardiovascular, renal, and metabolic. It also has an established medicines business, which includes off-patent franchises. The company sells its products globally, with the United States constituting close to one-third of total revenue.
80GF Score

Get the complete analysis for XSWX:NOVNEE

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF119.30
Price
CHF98.21
GF Value